Neil H. Stollman, MD, FACG
PostPost--treatment testing for treatment testing for ggHpHp eradication should be eradication should be
standardstandard--ofof--carecare
N il St ll MD FACGNeil Stollman MD, FACG
In the old days…In the old days…
• When treatment regimens were felt to be successful 90+% of the time, routine post-treatment testing (‘test-of-cure’) was felt to be unneccessary, and not cost effective
A till d i th t ll?• Are we still doing that well?
ACG Western Regional Postgraduate Course - Las Vegas, NV Copyright 2015 American College of Gastroenterology
1
Neil H. Stollman, MD, FACG
Recommended Primary Therapies for Recommended Primary Therapies for H. pylori H. pylori Infection: ACG GuidelinesInfection: ACG Guidelines
• Triple therapy: PPI + clarithromycin + amoxicillin (or metronidazole) for 14 days
• Quadruple therapy: PPI (or H2RA) + bismuth + tetracycline + metronidazole for 10 – 14 days
Chey WD, Wong BC. Am J Gastroenterol. 2007;102(8):1808-1825.
Rx Success for “Triple Therapy”Rx Success for “Triple Therapy”
%)
80
90
100
Tre
atm
ent
Su
cces
s (%
30
40
50
60
70
80
Eradication rates: █ >90%; █ 80%–90%; █ 70%–80%; █ <70%.Individual Treatment Studies
ITT
T
0
10
20
Graham DY, Fischbach L. Gut. 2010;59(8):1143-1153.
ACG Western Regional Postgraduate Course - Las Vegas, NV Copyright 2015 American College of Gastroenterology
2
Neil H. Stollman, MD, FACG
Rx Success for “Triple Therapy”Rx Success for “Triple Therapy”%
)
80
90
100 Only 18% of reports demonstrated eradication rates >85%~60% of reports demonstrated eradication rates <80%
Tre
atm
ent
Su
cces
s (%
30
40
50
60
70
80
Eradication rates: █ >90%; █ 80%–90%; █ 70%–80%; █ <70%.Individual Treatment Studies
ITT
T
0
10
20
Graham DY, Fischbach L. Gut. 2010;59(8):1143-1153.
HpHp Eradication Rates of Triple and Quad RxEradication Rates of Triple and Quad Rx
84 290
100
Clarithromycin triple therapy Bismuth quadruple therapy
68.965.6
81.379.3
81.6 78.7
67.4
54.5
77.672.5
84.2 80.678.9 78.9 80.0
74.7
30
40
50
60
70
80
90
Era
dic
atio
n R
ate
(%)
0
10
20
Overall (12 studies)
Eastern hemisphere(7 studies)
Western hemisphere(4 studies)
7 days of therapy
(4 studies)
10 days of therapy
(3 studies)
Active peptic ulcer(5 studies)
Non-ulcer dyspepsia(3 studies)
Dyspeptic symptoms (3 studies)
Adapted from Venerito M, et al. Digestion. 2013;88(1):33-45.
ACG Western Regional Postgraduate Course - Las Vegas, NV Copyright 2015 American College of Gastroenterology
3
Neil H. Stollman, MD, FACG
HpHp Antimicrobial Resistance U.S.Antimicrobial Resistance U.S.
Alaska 2000 to 20082United States 1998 to 20021
Antimicrobial Resistance of H. pylori Isolates
4230
20
19
Alaska, 2000 to 2008(n = 531 isolates)
2513
1
0LevofloxacinTetracyclineAmoxicillin
ClarithromycinMetronidazole
United States, 1998 to 20021
(n = 347 isolates)
NR
0 20 40 60
1. Duck WM, et al. Emerg Infect Dis. 2004;10(6):1088-1094.2. Tveit AH, et al. J Clin Microbiol. 2011;49(10):3638-3643.
0 10 20 30Resistance (%) Resistance (%)
100
90
Metro-sensitive Metro-
i
Clarithro-sensitive
Effect of Metronidazole and Clarithromycin Effect of Metronidazole and Clarithromycin Resistance on Treatment OutcomeResistance on Treatment Outcome
80
70
60
50
40
30
resistant
Clarithro-
rad
icat
ion
Rat
es (
%)
Luther J, et al. Am J Gastroenterol. 2010;105(1):65-73.
20
10
0
resistant
Quadruple therapy Triple therapy
Er
ACG Western Regional Postgraduate Course - Las Vegas, NV Copyright 2015 American College of Gastroenterology
4
Neil H. Stollman, MD, FACG
Predictors of Failure of EradicationPredictors of Failure of Eradication• Antimicrobial resistance
– Especially clarithromycin• Need to know patient’s antibiotic history
• Poor adherence• Re-treatment with initial (failed) regimen• Inadequate duration of therapy• Inadequate duration of therapy
1. Chey WD, Wong BC. Am J Gastroenterol. 2007;102(8):1808-1825.2. Saad RJ, Chey WD. Gastroenterol Hepatol Ann Rev. 2006;1:30-35.3. Zullo A, et al. J Clin Gastroenterol. 2012;46(4):259-261.
Effects of Adherence on OutcomeEffects of Adherence on Outcome• Patient nonadherence is an important factor
f lin treatment failure– Side effects are reported by app 50% of patients– Complicated treatment regimens
• Patients taking <80% of their treatment regimen have high rates of treatment failureregimen have high rates of treatment failure
• Treatment failure is associated with the emergence of antimicrobial resistance
Vakil N, Vaira D. J Clin Gastroenterol. 2013;47(5):383-388.
ACG Western Regional Postgraduate Course - Las Vegas, NV Copyright 2015 American College of Gastroenterology
5
Neil H. Stollman, MD, FACG
Symptomatology Is a Poor Marker for EradicationSymptomatology Is a Poor Marker for Eradication
• 87 adults with H. pylori–associated PUD treatedUBT fi d di ti i 70 (80%) ti t– UBT confirmed eradication in 70 (80%) patients
– Patients with successful eradication were significantly more likely to have symptomatic improvement than patients without eradication
BUT– A majority of eradicated patients still had symptoms– A majority of eradicated patients still used an H2RA or PPI
• Even if asymptomatic, 90% of patients queried were willing to have eradication testing
Fendrick AM, et al. Am J Med. 1999;107(2):133-136.
GuidelinesGuidelines
• ACG Guidelines (2007) recommend post-t t t t ti f PUD CA d ‘ i t ttreatment testing for PUD, CA and ‘persistent symptoms’.
• ESPHGHAN / NASPHGAN Guidelines 2011– “Even when children become asymptomatic after
treatment, it is recommended that the success of ,treatment ….. be evaluated. The absence of symptoms does not necessarily mean the infection has been eradicated.”
J Pediatr Gastroenterol Nutr 2011;53(2):230-43. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children.
ACG Western Regional Postgraduate Course - Las Vegas, NV Copyright 2015 American College of Gastroenterology
6
Neil H. Stollman, MD, FACG
Conclusion: Confirm Conclusion: Confirm HpHp death!death!• If, as Dr. Abraham asserts, the only good H. pylori is a
dead H pylori shouldn’t we confirm death?dead H. pylori, shouldn t we confirm death?• As eradication rates fall, it becomes increasingly
important to confirm successful treatment.• Symptom status is a poor marker of eradication• Knowledge is power
– Patients want to know, it’s reassuring to confirm eradication
• For adults, as is currently recommend for children, post-treatment testing-for-cure should be routine (unless and/or until we return to >90% Rx success)
Kill ‘em all? No!Kill em all? No!The case for selective H pyloricide…
Neil Stollman MD, FACGNeil Stollman MD, FACG
ACG Western Regional Postgraduate Course - Las Vegas, NV Copyright 2015 American College of Gastroenterology
7
Neil H. Stollman, MD, FACG
Historical PerspectiveHistorical Perspective
• 2012 marked the 30th anniversary of the yidentification of H. pylori, BUT Hp infection of humans dates back many thousands of years1
• Is our relationship with Hp one of parasitism or commensalism or symbiosis2
• Are there potential benefits of Hp infection?• Are the potential harms of Hp eradication?
1. Wang AY, Peura DA. Gastrointest Endosc Clin N Am. 2011;21(4):613-635. 2. Blaser MJ. Lancet. 1997;349(9057):1020-1022.
Are There Possible Benefits of Are There Possible Benefits of H. pyloriH. pylori Infection?Infection?
Obesity1
GERD2,3
Barrett’s esophagus8
Diarrhea9
Esophageal IBD7
1. Roper J, et al. J Clin Endocrinol Metab. 2008;93(6):2350-2357; 2. Raghunath A, et al. BMJ. 2003;326(7392):737; 3. Yaghoobi M, et al. Am J Gastroenterol. 2010;105(5):1007-1013; 4. Dellen ES, et al. Gastroenterology. 2011;141(5):1586-1592; 5. Chen Y, Blaser MJ. J Infect Dis. 2008;198(4):553-560; 6. Chen Y, Blaser MJ. Arch Intern Med. 2007;167(8):821-827; 7. Luther J, et al. Inflamm Bowel Dis. 2010;16(6):1077-1084; 8. Fischbach LA, et al. Helicobacter. 2012;17(3):163-175; 9. Cohen D, et al. Clin Infect Dis. 2012;54(4):e35-e42.
Dermatitis5
Allergy5,6 Asthma5,6
p gEosinophilia4 IBD7
ACG Western Regional Postgraduate Course - Las Vegas, NV Copyright 2015 American College of Gastroenterology
8
Neil H. Stollman, MD, FACG
Study ReferenceChile, Csendes et al 1997
Western Europe
Newton et al 1997
Pieramico and Zanetti 2000
H. pylori H. pylori Prevalence Among Patients With GERD Prevalence Among Patients With GERD
• Pooled analysis (20 studies):– Prevalence of Hp infection was
Gisbert et al 2001
Hackelsberger et al 1998
Manes et al 1999
Liston et al 1996
Werdmuller and Loffeld 1997
North America
Vaezi et al 2000
El-Serag et al 1999
Goldblum et al 1998
Varanasi et al 1998
Vicari et al 1998
Schubert and Schnell 1989
Fallone et al 2000
Far East
Prevalence of Hp infection was significantly lower in patients with GERD c/w those without GERD1
– Odds ratio (95% CI) = 0.60 (0.47–0.78)
• More recent meta-analysis (PUD pts)– Approximately two-fold increased
risk of developing new GERD among Shirota et al 1999
Wu et al 1999
Mihara et al 1996
Haruma et al 2000
Koike et al 2001
Summary
risk of developing new GERD among those with successful eradication versus those with persistent infection2
1. Raghunath A, et al. BMJ. 2003;326(7392):737.2. Yaghoobi M, et al. Am J Gastroenterol. 2010;105(5):1007-1013.
0.10
Odds Ratio
0.16 0.25 0.40 0.63 1.00 1.58 2.51 3.98
Not All Not All H. pylori H. pylori Are Created EqualAre Created Equal• Vacuolating cytotoxin VacA
h i i i l d ( PAI)• cag pathogenicity island (cag-PAI)• babA2
Perhaps there are ‘good’ andare good and‘bad’ Hp?
Image from Suerbaum S, Michetti P.2
ACG Western Regional Postgraduate Course - Las Vegas, NV Copyright 2015 American College of Gastroenterology
9
Neil H. Stollman, MD, FACG
Might Might H. pylori H. pylori Protect Against Barrett’s Esophagus Protect Against Barrett’s Esophagus and Esophageal Adenocarcinoma?and Esophageal Adenocarcinoma?
Barrett’s esophagus1
• Meta anal sis (49 st dies) Hp infec on associated ith ↓risk of BE• Meta-analysis (49 studies): Hp infec on associated with ↓risk of BE– RR = 0.73 (95% CI = 0.60–0.88)– Significant heterogeneity (P < 0.0001)
• 4 studies of ‘high quality’ – RR = 0.46 (95% CI = 0.35–0.60)
• 7 studies examined cag A-positive H. pylori– RR = 0.38 (95% CI = 0.19–0.78)
Esophageal adenocarcinoma2Esophageal adenocarcinoma2
• Case-control study >128K patients• Hp+ patients one-third as likely as Hp- patients to develop
adenocarcinoma of the esophagus (after adjustment for BMI, cigarette smoking, and education)
1. Fischbach LA, et al. Helicobacter. 2012;17(3):163-175; 2. de Martel C, et al. J Infect Dis. 2005;191(5):761-767.
H. pylori H. pylori and and Diarrheal IllnessesDiarrheal Illnesses• 2477 European children (5–8 years)1
76 1H. pylori + H. pylori -P<0.001
76.1
16.66.6 0.7
54.3
32.5
11.91.3
0
20
40
60
80
Never Rarely Sometimes Often
Su
bje
cts
(%)
Diarrhea in the prior 3 months
• Similar results observed in Israeli adult males2Similar results observed in Israeli adult males
• Potential mechanisms
– H. pylori induces an inflammatory infiltrate, which protects against diarrhea-inducing infections1
– Potential antimicrobial activity of cecropin-like peptide3
1. Rothenbacher D, et al. J Infect Dis. 2000;182(5):1446-1449; 2. Cohen D, et al. Clin Infect Dis. 2012;54(4):e35-e42; 3. Pütsep K, et al. Nature. 1999;398(6729):671-672.
ACG Western Regional Postgraduate Course - Las Vegas, NV Copyright 2015 American College of Gastroenterology
10
Neil H. Stollman, MD, FACG
Study ID RR (95% CI) % Weight
el-Omar 0.42 (0.28, 0.63) 4.59Mantzaris 0.57 (0.40, 0.82) 4.86Meining 0 23 (0 07 0 74) 1 46
HpHp Infection in IBD patients vs ControlsInfection in IBD patients vs Controls
Meining 0.23 (0.07, 0.74) 1.46Oberhuber 0.87 (0.59, 1.26) 4.73Parente 0.82 (0.69, 0.98) 5.95Wagtmans 0.34 (0.25, 0.47) 5.17Duggan 0.95 (0.73, 1.23) 5.50Corrado 0.07 (0.00, 1.10) 0.32D’Inca 0.73 (0.45, 1.17) 4.11Pearce 0.69 (0.34, 1.38) 2.90Parente 0.76 (0.61, 0.95) 5.70Parlak 1.05 (0.85, 1.30) 5.76Vare 0.66 (0.46, 0.95) 4.82Feeney 1 0.32 (0.14, 0.72) 2.41Feeney 2 0.90 (0.51, 1.61) 3.53Furusu 0.57 (0.32, 1.00) 3.56Guslandi 0.41 (0.19, 0.88) 2.61P i 0 94 (0 63 1 42) 4 56Pascasio 0.94 (0.63, 1.42) 4.56Piodi 0.77 (0.57, 1.05) 5.21Triantafillidis 0.63 (0.46, 0.84) 5.25Pronai 0.33 (0.20, 0.53) 4.10Oliveira 1 1.02 (0.71, 1.47) 4.83Oliveira 2 0.73 (0.52, 1.01) 5.03Sladek 0.25 (0.13, 0.49) 3.04
Luther J, et al. Inflamm Bowel Dis. 2010;16(6):1077-1084.
0.1 51
Overall (I-squared = 75.8%, P=0.000) 0.64 (0.54, 0.75) 100.00
HpHp: Reduced Risk for Atopic Disorders: Reduced Risk for Atopic DisordersAsthma and dermatitis1
1. Chen Y, Blaser MJ. J Infect Dis. 2008;198(4):553-560.
Childhood H. pylori (and an antigen rich environment) may be important to development of the immune system2
ACG Western Regional Postgraduate Course - Las Vegas, NV Copyright 2015 American College of Gastroenterology
11
Neil H. Stollman, MD, FACG
Association of Association of H. pylori H. pylori and Asthmaand AsthmaH. pylori + H. pylori – Odds Ratio Odds Ratio
Study Events Total Events Total WeightM-H, Random,
95% CIM-H, Random,
95% CI
A. Baccioglu 2008 8 74 5 16 1.0% 0.27 [0.07, 0.97]
Anne McCune 2002 68 1079 171 2165 11.1% 0.78 [0.59, 1.05]
Asbjoms dottir H 2006 23 175 39 267 4.5% 0.88 [0.51, 1.54]
D. Jarvis 2004 60 208 167 613 8.9% 1.08 [0.76, 1.53]
Donna Fullerton 2008 62 643 151 1732 10.3% 1.12 [0.82, 1.52]
Noam Zevit 2008 233 3175 345 3784 17.2% 0.79 [0.66, 0.94]
W. Uter 2003 121 243 495 990 11.5% 0.99 [0.75, 1.31]
Yu Chen 2007 229 3720 296 3943 16.9% 0.81 [0.68, 0.97]
Yu Chen 2008 267 2625 679 4787 18.6% 0.69 [0.59, 0.80]
Wang Q, et al. Helicobacter. 2013;18(1):41-53.
Total (95% CI) 11942 18297 100.0% 0.84 [0.74, 0.96]
Total events 1071 2348
Heterogeneity: τ2 = 0.02; χ2 = 16.63, df = 8 (p = 0.03); I2 = 52%
Test for overall effect: Z = 2.64 (p = 0.008) 0.01 0.1 1 10 100
Favors experimental Favors control
Association of Association of HpHp andand Esophageal EosinophiliaEsophageal Eosinophilia
• US Pathology Database
• 165,017 patients in the U.S. who underwent esophageal and gastric biopsies from 2008 to 2010
Esophageal eosinophilia histologically
consistent with EoE
No esophageal eosinophilia
Unadjusted OR(95% CI)
Adjusted OR(95% CI)a
Unadjusted and Adjusted ORs for the Association Between Esophageal Eosinophilia and H. pylori Gastritis
Dellen ES, et al. Gastroenterology. 2011;141(5):1586-1592.
EoE eosinophilia (95% CI) (95% CI)
Normal gastric biopsy specimens
841 30,481 1.00 (ref) 1.00 (ref)
Chronic active gastritis without H. pylori 44 1851 0.86 (0.64–1.17) 1.01 (0.74–1.38)
Chronic active gastritis with H. pylori 193 10,131 0.69 (0.59–0.81) 0.79 (0.68–0.93)
ACG Western Regional Postgraduate Course - Las Vegas, NV Copyright 2015 American College of Gastroenterology
12
Neil H. Stollman, MD, FACG
Data in support of Data in support of HpHp eradication NUD inconsistenteradication NUD inconsistent• 337 patients with NUD and H. pylori
infection randomized to:Omeprazole + amoxicillin +– Omeprazole + amoxicillin + clarithromycin x 14 days
– Placebo• At 12 months, no difference in:
– Relief of symptoms– Rate of antacid use– Most SF-36 scores ea
n S
ymp
tom
Sco
re
Omeprazole, amoxicillin, and clarithromycin
Placebo
3
2
1
– Development of PUD
Talley NJ, et al. N Engl J Med. 1999;341(15):1106-1111.
Me
0
Finally, current Finally, current ACG ACG Guidelines (as flawed as they are) Guidelines (as flawed as they are) do NOT recommend universal eradicationdo NOT recommend universal eradication
• Established indications for diagnosis and treatmentActi e PUD– Active PUD
– Confirmed history of PUD (not previously treated for H. pylori)– Gastric MALT lymphoma (low grade)– After endoscopic resection of early gastric cancer– Uninvestigated dyspepsia (depending upon H. pylori prevalence)
• Controversial indications for diagnosis and treatment– Non-ulcer dyspepsia– GERD– Persons using NSAIDs– Unexplained iron deficiency anemia– Populations at higher risk for gastric cancer
Chey WD, Wong BC. Am J Gastroenterol. 2007;102(8):1808-1825.
ACG Western Regional Postgraduate Course - Las Vegas, NV Copyright 2015 American College of Gastroenterology
13
Neil H. Stollman, MD, FACG
Most Most people people with with H. pylori H. pylori diedie with itwith it, , not not because of itbecause of it..
The widespread eradication of H. pylori could have unintended consequences,
such as possible increased IBD, allergies, asthma, GERD/BE, diarrhea….not to mention the
consequences of widespread antibiotic overuse
ConclusionConclusion
• In many cases, H. pylori infection is asymptomatic and could possibly beasymptomatic and could possibly be beneficial. In asymptomatic individuals without increased gastric cancer risk, there is no reason to test for infection
• Selective testing and treating, particularly in symptomatic and/or high risk populationssymptomatic and/or high risk populations only, is the recommended and most appropriate current strategy.
ACG Western Regional Postgraduate Course - Las Vegas, NV Copyright 2015 American College of Gastroenterology
14